AI assistant
Citius Pharmaceuticals, Inc. — Director's Dealing 2017
Dec 13, 2017
34965_dirs_2017-12-13_d605e6ec-4136-4058-821d-f969f7155fee.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Citius Pharmaceuticals, Inc. (CTXR)
CIK: 0001506251
Period of Report: 2017-11-27
Reporting Person: Bartushak Jaime (Chief Financial Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 60353 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Purchase Common Stock) | $3.45 | 2027-09-15 | Common Stock (25000) | Direct | |
| Stock Option (Right to Purchase Common Stock) | $10.50 | 2026-07-16 | Common Stock (48267) | Direct |
Footnotes
F1: On September 15,2017 the Reporting Person was granted a ten-year option to purchase 25,000 shares of common stock at an exercise price of $3.45 per share. The options vest as follows: 8,333 shares vest on September 13, 2018, and then 694 shares per month for the next 24 months.
F2: On July 6, 2016 the Reporting Person was granted a ten-year option to purchase 48,267 shares of common stock at an exercise price of $10.50 per share. The options vest as follows: 16,089 shares vest on July 7, 2017,
and then 1,341 shares per month for the next 24 months.